74 related articles for article (PubMed ID: 22725663)
1. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism.
He X; Mo L; Li ZY; Tan ZR; Chen Y; Ouyang DS
Xenobiotica; 2012 Dec; 42(12):1248-54. PubMed ID: 22725663
[TBL] [Abstract][Full Text] [Related]
2. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
3. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.
Juan H; Terhaag B; Cong Z; Bi-Kui Z; Rong-Hua Z; Feng W; Fen-Li S; Juan S; Jing T; Wen-Xing P
Eur J Clin Pharmacol; 2007 Jul; 63(7):663-8. PubMed ID: 17468862
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
[TBL] [Abstract][Full Text] [Related]
5. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers.
Fan L; Mao XQ; Tao GY; Wang G; Jiang F; Chen Y; Li Q; Zhang W; Lei HP; Hu DL; Huang YF; Wang D; Zhou HH
Xenobiotica; 2009 Mar; 39(3):249-54. PubMed ID: 19280523
[TBL] [Abstract][Full Text] [Related]
6. Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.
Zeng Y; He FY; He YJ; Dai LL; Fan L; Zhou HH
Xenobiotica; 2009 Nov; 39(11):844-9. PubMed ID: 19845435
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
[TBL] [Abstract][Full Text] [Related]
8. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
9. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.
Siegmund W; Ludwig K; Giessmann T; Dazert P; Schroeder E; Sperker B; Warzok R; Kroemer HK; Cascorbi I
Clin Pharmacol Ther; 2002 Nov; 72(5):572-83. PubMed ID: 12426521
[TBL] [Abstract][Full Text] [Related]
10. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
11. High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.
Nguyen MA; Staubach P; Tamai I; Langguth P
Eur J Pharm Sci; 2015 Feb; 68():36-42. PubMed ID: 25486333
[TBL] [Abstract][Full Text] [Related]
12. MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males.
Zhang WX; Chen GL; Zhang W; Tan ZR; Liu J; Zhou G; Hu DL; Zhou HH
Clin Chim Acta; 2005 Sep; 359(1-2):46-52. PubMed ID: 16170863
[TBL] [Abstract][Full Text] [Related]
13. No sex difference in overall P-glycoprotein activity as assessed by talinolol disposition in humans.
Long B; Su YQ; Xia Y; Zou YY; Tang B; Chen ZJ; Lin Y
Int J Clin Pharmacol Ther; 2016 Mar; 54(3):157-62. PubMed ID: 26784939
[TBL] [Abstract][Full Text] [Related]
14. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants.
Xiao CQ; Chen R; Lin J; Wang G; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2012 Feb; 42(2):173-8. PubMed ID: 21943317
[TBL] [Abstract][Full Text] [Related]
15. The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis.
Liu YY; Li C; Cui Z; Fu X; Zhang S; Fan LL; Ma J; Li G
Gene; 2013 Dec; 531(2):476-88. PubMed ID: 24042126
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
Bogman K; Zysset Y; Degen L; Hopfgartner G; Gutmann H; Alsenz J; Drewe J
Clin Pharmacol Ther; 2005 Jan; 77(1):24-32. PubMed ID: 15637528
[TBL] [Abstract][Full Text] [Related]
17. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
[TBL] [Abstract][Full Text] [Related]
18. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
19. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
20. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets.
Siegmund W; Ludwig K; Engel G; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Weitschies W
J Pharm Sci; 2003 Mar; 92(3):604-10. PubMed ID: 12587122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
